Abstract 1651
Background
Biosimilar development applies a totality of evidence approach, in which Phase I (pharmacokinetic [PK]/pharmacodynamics [PD]) studies have a pivotal role. Phase I studies are particularly important in biosimilar pegfilgrastim development due to high inter-subject variability (ISV) mainly linked to target-mediated clearance.1 A pivotal Phase I study confirmed that Sandoz proposed biosimilar pegfilgrastim (LA-EP2006) and EU-reference biologic have matching PK/PD profiles.2 For FDA approval of LA-EP2006, a bridging study is necessary to confirm that PK/PD properties of LA-EP2006 match EU and US reference pegfilgrastim. This Phase I bridging study is ongoing and here we present the methodology.
Methods
To meet FDA requirements of LA-EP2006, EU and US reference pegfilgrastim PK/PD similarity, and to address ISV, a three-way crossover design was chosen following FDA advice. The study was sufficiently powered (90%) to achieve confidence intervals within margins 0.8–1.25 in co-primary endpoints pairwise comparisons.
Results
Due to historically known high intra- and inter-subject variabilities with reference biologic (CV: 45% and ∼80%, respectively)3 in AUC0-inf, a randomized, double-blind, single-dose, 3-treatment, 6-sequence crossover, Phase I study in healthy volunteers is suitable to demonstrate similarity of PK/PD, safety and immunogenicity between LA-EP2006, EU and US reference pegfilgrastim. Multiple centers, regions, contract research organizations and medicine batches are required, which further amplifies operational complexity of study conduct and scientific standards. The study is ongoing in 5 US and 1 Dutch study sites.
Conclusions
Phase I methodology applying a 3-way crossover design addresses known high ISV with pegfilgrastim and establishes the scientific bridge between proposed biosimilar and reference US and EU biologics. References 1. Yang et al. Clin Pharmacokinet 2011;50:295–306. 2. Nakov et al. Poster presented at SABCS 2017 (P3-14-10). 3. Yang et al. Cancer Chemother Pharmacol 2015;75:1199–206.
Clinical trial identification
Legal entity responsible for the study
Hexal AG, Holzkirchen, Germany.
Funding
Hexal AG, Holzkirchen, Germany.
Editorial Acknowledgement
Caroline McGown, Spirit Medical Communications.
Disclosure
R. Nakov, S. Schier-Mumzhiu, A. Skerjanec, A. Bellon, A. Krendyukov, G. Otto: Employee: Hexal AG. S. Schussler, J. Wang: Employee: Sandoz Inc.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract